RECURRENT PRIMARY PERITONEAL CARCINOMA
Clinical trials for RECURRENT PRIMARY PERITONEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY PERITONEAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY PERITONEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial underway
Disease control OngoingThis study looks at three different drug combinations for women with ovarian, fallopian tube, or primary peritoneal cancer that has returned and is no longer responding to platinum-based chemotherapy. The trial compares a standard chemotherapy drug (pegylated liposomal doxorubici…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 23:58 UTC
-
Measles virus reprogrammed to attack ovarian cancer shows promise in early trial
Disease control OngoingThis study tests a new treatment for ovarian cancer that has come back after standard therapy. It uses stem cells loaded with a modified measles virus to deliver cancer-killing effects directly into the abdomen. The trial involves 34 participants and aims to find the safest dose …
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 16, 2026 23:57 UTC
-
New drug combo may offer alternative to chemo for ovarian cancer
Disease control OngoingThis study tested whether the targeted drugs olaparib (alone or with cediranib) work better than standard platinum-based chemo for women with ovarian, fallopian tube, or peritoneal cancer that came back after initial treatment. About 579 women with platinum-sensitive cancer took …
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 23:57 UTC
-
New drug combo shows promise for recurrent ovarian and endometrial cancers
Disease control OngoingThis early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in about 31 people whose endometrial, ovarian, or related cancers have returned. The main goal is to find the safest dose and understand side effects. Participants must have ce…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 16, 2026 23:56 UTC
-
New drug combo shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, APG-1252 and cobimetinib, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the drugs can shrink or stabilize tumors. About 42 adults with advanced or recurrent cance…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 23:56 UTC
-
New combo aims to stall ovarian Cancer's return
Disease control OngoingThis study tests whether combining an immunotherapy drug (pembrolizumab) with chemotherapy (carboplatin) can delay cancer progression in people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. Participants have a rising CA-125 blood marker but no visi…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 16, 2026 23:55 UTC
-
Engineered immune cells take on Hard-to-Treat ovarian cancer
Disease control OngoingThis early-stage trial tests a new treatment for ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to standard therapy. Patients receive their own immune cells (T cells) that have been genetically modified to recognize and attack cancer cells, along…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding the experimental drug AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 participants will receive either the combination…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug combo shows promise for recurrent ovarian cancer in early trial
Disease control OngoingThis early-phase trial tests whether adding an experimental drug (berzosertib) to standard chemotherapy (carboplatin and gemcitabine) is safe and effective for people with ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 participan…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Heated chemo during surgery may fight recurrent ovarian cancer
Disease control OngoingThis early-phase study tests the safety and effectiveness of giving heated chemotherapy directly into the abdomen during surgery for advanced or recurrent ovarian, fallopian tube, uterine, or peritoneal cancer. About 40 participants will receive this treatment, with some also get…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New combo therapy offers hope for Tough-to-Treat cancers
Disease control OngoingThis study tests two drug combinations (olaparib plus either AZD2014 or AZD5363) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The goal is to find the safest dose and see if the drugs can slow or stop tumor growth. About 159 adults who…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for ovarian cancer patients whose tumors outsmart current drugs
Disease control OngoingThis study tests a drug called adavosertib, given alone or with another drug (olaparib), in women with ovarian, fallopian tube, or peritoneal cancer that has returned and stopped responding to PARP inhibitors. About 96 participants will receive one of the two treatments to see if…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New drug duo shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New Triple-Drug cocktail shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests a new three-drug combination (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the combination shrinks tumors and to check for si…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Floor Backes, MD • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Promising drug cocktail targets Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests a combination of two drugs, veliparib and topotecan, in people with solid tumors or ovarian cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combo can shrink tumors. About 88 adults are taking part in this early…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New hope for Drug-Resistant ovarian cancer: experimental combo shows promise
Disease control OngoingThis study tests whether adding an experimental drug called M6620 to standard chemotherapy (gemcitabine) works better than gemcitabine alone for women with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 70 par…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New drug duo targets Hard-to-Treat brain tumors
Disease control OngoingThis early-phase trial tests a new drug (MLN0128) combined with bevacizumab in people with recurrent glioblastoma (a brain cancer) or other advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand side ef…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis study compares two treatments for women with ovarian, fallopian tube, or peritoneal cancer that has come back after initial therapy. One group gets olaparib alone, the other gets olaparib plus tremelimumab. Olaparib blocks cancer cells from repairing themselves, while tremel…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New combo aims to outsmart Drug-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
New hope for recurrent ovarian cancer: drug combo extends life?
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with ovarian, peritoneal, or fallopian tube cancer that has come back live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus beva…
Matched conditions: RECURRENT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC